Guardant Health, Inc. (NASDAQ:GH) Shares Purchased by SWS Partners

SWS Partners boosted its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 44.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,888 shares of the company's stock after buying an additional 37,126 shares during the period. Guardant Health accounts for approximately 1.1% of SWS Partners' portfolio, making the stock its 20th biggest holding. SWS Partners owned about 0.10% of Guardant Health worth $3,693,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JNBA Financial Advisors acquired a new position in Guardant Health in the 3rd quarter valued at $26,000. R Squared Ltd acquired a new stake in Guardant Health in the fourth quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new position in shares of Guardant Health in the third quarter valued at $34,000. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the fourth quarter worth about $43,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Guardant Health by 168.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company's stock worth $79,000 after purchasing an additional 2,153 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

Shares of NASDAQ GH traded down $0.85 during trading on Friday, reaching $39.32. The stock had a trading volume of 2,314,557 shares, compared to its average volume of 2,476,829. The stock has a market cap of $4.85 billion, a PE ratio of -11.04 and a beta of 1.50. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89. The firm's 50 day moving average price is $41.88 and its two-hundred day moving average price is $32.32.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Ratings Changes

GH has been the topic of several recent research reports. Morgan Stanley upped their price objective on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday. Stifel Nicolaus increased their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Scotiabank lifted their price target on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Monday, February 24th. Canaccord Genuity Group boosted their price target on Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Finally, The Goldman Sachs Group boosted their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $48.40.

Insiders Place Their Bets

In other news, Director Musa Tariq sold 2,320 shares of the company's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares in the company, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 2,668 shares of company stock valued at $95,208 over the last quarter. Insiders own 5.50% of the company's stock.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.